Swedish Institute for Health Economics, Lund, Sweden.
BMJ Open. 2013 Jan 10;3(1):e001563. doi: 10.1136/bmjopen-2012-001563.
To evaluate the cost effectiveness of a multidisciplinary team including a pharmacist for systematic medication review and reconciliation from admission to discharge at hospital among elderly patients (the Lund Integrated Medicines Management (LIMM)) in order to reduce drug-related readmissions and outpatient visits.
Published data from the LIMM project group were used to design a probabilistic decision tree model for evaluating tools for (1) a systematic medication reconciliation and review process at initial hospital admission and during stay (admission part) and (2) a medication report for patients discharged from hospital to primary care (discharge part). The comparator was standard care. Inpatient, outpatient and staff time costs (Euros, 2009) were calculated during a 3-month period. Dis-utilities for hospital readmissions and outpatient visits due to medication errors were taken from the literature.
The total cost for the LIMM model was €290 compared to €630 for standard care, in spite of a €39 intervention cost. The main cost offset arose from avoided drug-related readmissions in the Admission part (€262) whereas only €66 was offset in the Discharge part as a result of fewer outpatient visits and correction time. The reduced disutility was estimated to 0.005 quality-adjusted life-years (QALY), indicating that LIMM was a dominant alternative. The probability that the intervention would be cost-effective at a zero willingness to pay for a gained QALY compared to standard care was estimated to 98%.
The LIMM medication reconciliation (at admission and discharge) and medication review was both cost-saving and generated greater utility compared to standard care, foremost owing to avoided drug-related hospital readmissions. When implementing such a review process with a multidisciplinary team, it may be important to consider a learning curve in order to capture the full advantage.
评估一个多学科团队(包括药剂师)在医院内为老年患者(伦德综合药物管理[LIMM])进行系统药物审查和用药重整的成本效益,以减少药物相关的再入院和门诊就诊次数。
使用来自 LIMM 项目组的已发表数据来设计一个概率决策树模型,用于评估(1)初始入院和住院期间(入院部分)的系统药物重整和审查流程,以及(2)从医院出院到初级保健的药物报告(出院部分)的工具。对照组为标准护理。在 3 个月期间计算了住院、门诊和员工时间成本(欧元,2009 年)。药物错误导致的住院和门诊就诊的非使用效用来自文献。
LIMM 模型的总成本为 290 欧元,而标准护理为 630 欧元,尽管干预成本为 39 欧元。主要的成本节省来自入院部分的药物相关再入院减少(262 欧元),而由于门诊就诊次数和更正时间减少,出院部分仅节省 66 欧元。减少的非使用效用估计为 0.005 个质量调整生命年(QALY),表明 LIMM 是一种优势选择。与标准护理相比,干预措施在零意愿支付一个获得的 QALY 的情况下具有成本效益的概率估计为 98%。
与标准护理相比,LIMM 的药物重整(入院和出院)和药物审查既节省成本又增加了效用,主要是因为避免了药物相关的住院再入院。在实施这种多学科团队审查流程时,考虑学习曲线以充分利用其优势可能很重要。